The Science of Psychedelics for Mental Health | Dr. Robin Carhart-Harris

概览

Andrew Huberman speaks with Dr. Robin Carhart-Harris about classic psychedelics, especially psilocybin, LSD, DMT, and 5-MeO-DMT, and how they may alter brain networks, subjective experience, and mental health outcomes. The episode repeatedly distinguishes clinical psychedelic therapy from recreational use and does not present psychedelics as something everyone should take.

The central argument is that classic psychedelics are not just receptor-active drugs; their therapeutic relevance may depend on the subjective experience: confronting difficult material, “letting go,” emotional release, insight, and later integration. Carhart-Harris also stresses that much of the field is still developing, with promising but sometimes unpublished or early-stage evidence.

The discussion moves from definitions and dosing into trial design, brain imaging, depression, anorexia, fibromyalgia, MDMA-assisted therapy, DMT, ego dissolution, relapse, legal status, and the need for professional safeguards. A recurring conclusion is that psychedelic therapy may represent a genuine shift from daily pharmacotherapy, but only if it is studied, regulated, and delivered carefully.

分段落总结

[00:00] Guest and Episode Scope

[事实] Huberman introduces Dr. Robin Carhart-Harris as a UCSF professor of neurology and psychiatry and a leading researcher on psychedelics and brain circuitry.

[事实] The episode covers psilocybin, LSD, DMT, depression, other psychiatric challenges, creativity, intelligence, clinical trials, law, and therapeutic mechanisms.

[事实] Huberman states that psilocybin trials have shown relief of major depression in more than 67% of people taking appropriate dosages, while also saying this does not mean everyone should take psilocybin.

[03:00] What “Psychedelic” Means

[事实] Carhart-Harris explains that Humphry Osmond coined “psychedelic” after rejecting the older framing of these drugs as merely psychosis-mimicking.

[事实] He describes the term as referring to the revealing or manifesting of the mind or psyche, with experiences that can be “hellish” or “heavenly.”

[事实] He says classic psychedelics can also be defined pharmacologically by their action at the serotonin 2A receptor, but argues that subjective experience cannot be ignored.

[09:00] The Unconscious and Psyche-Revealing Effects

[事实] Carhart-Harris distinguishes blind sight and non-conscious processing from the psychoanalytic unconscious, which includes painful, repressed, personal, and transpersonal material.

[事实] He says classic psychedelics such as LSD and psilocybin can bring difficult memories, trauma-related material, emotional release, and insight into awareness.

[推测] The episode frames “psyche revealing” as central to why classic psychedelics have attracted therapeutic interest beyond drugs such as ketamine, MDMA, or cannabis.

[15:00] Microdosing, Placebo, and Dose Calibration

[事实] Carhart-Harris defines microdosing as using a dose of a classic psychedelic that does not produce a noticeable psychedelic altered state.

[事实] He says an LSD microdose is often discussed around 10 to 12 micrograms, while noting that some sensitive people may perceive effects at that range.

[事实] He describes evidence for microdosing as thin and cites a self-blinding citizen-science LSD microdosing study in which microdosing did not compellingly beat placebo.

[事实] He estimates very broadly that one gram of magic mushrooms may contain around 10 milligrams of psilocybin, while warning that this is uncertain and should not be used for self-dosing.

[24:00] Psilocybin Therapy Setting

[事实] The discussion describes psilocybin therapy sessions using eye masks, eyes closed, music, and typically two guides or clinicians present.

[事实] Carhart-Harris says music is a staple component across psychedelic therapy trials, but also notes that its role has not been properly tested.

[推测] The therapy model is presented as a combined intervention: the drug, the environment, the music, and the therapeutic relationship may interact.

[33:00] Trust, Let Go, Be Open

[事实] Carhart-Harris identifies “trust, let go, be open” as a guiding principle learned through psychedelic therapy work and mentorship from Hopkins researchers.

[事实] He says trust relates to therapeutic rapport, letting go relates to surrender or non-resistance, and openness involves willingness to confront difficult material.

[事实] He says readiness to let go is measured in trials and predicts therapeutic response.

[事实] He describes the early psychedelic phase as often involving anxiety, struggle, fear of dying, or fear of losing one’s mind.

[42:00] Brain Connectivity During the Trip

[事实] Carhart-Harris describes imaging findings in which psilocybin, LSD, and DMT increase global functional connectivity and reduce modularity in the brain.

[事实] He says brain communication usually occurs mostly within systems, while psychedelics increase communication across modules.

[事实] He says this cross-module connectivity correlates with the magnitude of subjective effects.

[推测] The discussion suggests, while avoiding strong causal claims, that increased brain flexibility may relate to psychological flexibility.

[48:00] Non-Hallucinogenic Psychedelic-Like Drugs

[事实] Huberman asks about attempts to create drugs that activate psychedelic-relevant pathways without hallucinations.

[事实] Carhart-Harris says pharma, smaller startups, patients, and the medical system may all be interested in treatments that work without producing a trip.

[事实] He argues that if a drug lacks psyche-revealing subjective effects, it may not be “psychedelic” in the original sense, even if it acts on serotonin 2A receptors.

[55:09] After-Effects, Depression, and Network Flexibility

[事实] Carhart-Harris says increased global connectivity has been seen after psilocybin therapy in two depression cohorts: the next day in one study and three weeks later in another.

[事实] He says the magnitude of decreased modularity or increased global connectivity correlated with improvement in depression symptom severity.

[事实] He cautions that sharper cognition can also be associated with more modularity, so the modularity story should not be overextended.

[推测] The episode interprets depression as a state of being stuck in a mental and neural “rut,” where opening the system may help restore flexibility.

[64:03] Macrodose Sessions and Anorexia Trial

[事实] Carhart-Harris says evidence is more compelling for one, two, or three macrodose sessions in controlled, safe settings than for microdosing.

[事实] He says psychedelic therapy dosing sessions are commonly spaced one, two, or three weeks apart, with two sessions often used at Hopkins, Imperial, and NYU.

[事实] He describes an ongoing psilocybin therapy trial for anorexia using three sessions, with exciting but not yet published results.

[事实] He reports seeing reduced obsessive thoughts about food, greater willingness to eat healthier amounts, and improved weight at long follow-up in that trial.

[66:34] Integration After the Session

[事实] Carhart-Harris says integration can last a lifetime, because the psychedelic session may make difficult psychological work easier but does not complete all of it.

[事实] He compares integration to a practice, similar to meditation, where ongoing attention and maintenance matter.

[事实] He suggests meditation, mindfulness, and spiritual practice may complement psychedelic therapy by helping people sit with experience rather than suppress it.

[推测] The episode treats post-session integration as essential for turning acute insights into durable change.

[73:24] First-Time Psilocybin Study in Healthy Volunteers

[事实] Carhart-Harris describes a completed but unpublished study of healthy, middle-aged volunteers who had never used psychedelics before.

[事实] The study used a placebo dose of one milligram and a larger 25 milligram psilocybin dose, with EEG during sessions and MRI before and after.

[事实] He says the 25 milligram dose produced psychological and neurobiological changes, including improved well-being and increased informational complexity in EEG activity.

[82:04] Anatomical Brain Changes and Cognitive Flexibility

[事实] Carhart-Harris says diffusion tensor imaging showed changes in major white matter tracts between prefrontal cortex, thalamus, and striatum after one 25 milligram psilocybin session.

[事实] He says the finding was strengthened after independent reanalysis with free-water correction, but emphasizes it remains one study and needs caution.

[事实] He reports improved cognitive flexibility after 25 milligrams, but not after the placebo dose.

[推测] The study is presented as evidence that psilocybin may affect both subjective well-being and measurable brain structure, though functional meaning remains uncertain.

[83:50] Fibromyalgia and Chronic Pain

[事实] Carhart-Harris describes fibromyalgia as generalized chronic pain rather than localized pain such as lower back pain.

[事实] He says the fibromyalgia psilocybin therapy study used one 25 milligram dose, eye masks, EEG, and a clinical population.

[事实] He notes possible links between trauma, inflammation, and fibromyalgia, but warns against assuming buried trauma will be uncovered in every case.

[事实] He says the team had treated about eight people and that the work was going very well, while explicitly managing expectations.

[89:01] MDMA Versus Classic Psychedelics

[事实] Carhart-Harris says MDMA therapy is closer to traditional talk therapy, with more dialogue and interpersonal connection than classic psychedelic therapy.

[事实] He says MDMA trials likely use eye masks less than psilocybin therapy, because MDMA can increase connection with facilitators.

[事实] He describes MDMA as more directionally positive and useful in PTSD because it can help people revisit trauma while feeling safer and more trusting.

[推测] The episode presents MDMA as less likely than classic psychedelics to force deep confrontation, but potentially more tolerable for trauma work.

[93:02] Expectancy and Psilocybin Versus Escitalopram

[事实] In the psilocybin therapy versus escitalopram trial, participants had higher expectations for psilocybin on average.

[事实] Carhart-Harris says expectancy predicted response to escitalopram across many measures but did not predict response to psilocybin therapy.

[推测] This weakens the claim that psilocybin therapy’s effects are merely placebo or expectancy-driven, though the mechanism remains unresolved.

[96:58] Why LSD Is Studied Less Often

[事实] Carhart-Harris says LSD was historically more stigmatized and harder to study, while psilocybin research benefited from existing precedent.

[事实] He says LSD trips are often eight hours or longer and dose-dependent, making clinical and imaging studies more logistically difficult.

[事实] He contrasts LSD’s long duration with psilocybin’s roughly four-to-six-hour duration and MDMA’s similar range.

[102:57] Combining Psilocybin and MDMA

[事实] Huberman asks about underground therapeutic use of psilocybin combined with MDMA.

[事实] Carhart-Harris says underground therapists do use this combination and that there may be something to learn from trial-and-error practice, while speaking cautiously as a scientist.

[事实] He says psilocybin can reach deep suffering aggressively, while MDMA may make it easier to approach traumatic material safely.

[推测] Combination therapy is presented as a possible future precision-medicine question, not as an established clinical recommendation.

[109:36] DMT, 5-MeO-DMT, and Extreme Short-Duration Experiences

[事实] Huberman describes DMT as brief but profoundly intense based on reports from therapeutic contexts involving veterans.

[事实] Carhart-Harris calls DMT a classic psychedelic and direct serotonin 2A agonist, while noting that its potency depends on dose and receptor affinity.

[事实] He distinguishes DMT from 5-MeO-DMT, saying 5-MeO-DMT is often described as less visual and more reliably associated with ego dissolution.

[114:38] Ego Dissolution and the “Recent Brain”

[事实] Carhart-Harris defines ego dissolution through loosened boundaries between self, others, and the world, with a positive feeling of interconnectedness.

[事实] He says serotonin 2A receptors are heavily expressed in evolutionarily recent cortex, which humans have more of than other species.

[事实] He hypothesizes that classic psychedelics affect this “egoic brain” by increasing entropic brain activity and spreading out system dynamics.

[推测] Ego dissolution is framed as therapeutically powerful when it loosens rigid self-boundaries, but potentially unstable if not integrated.

[123:34] Relapse, Limits, and Need for More Treatment

[事实] Carhart-Harris says worsening after trials is very rare in their work, but relapse is common after three months or more in treatment-resistant depression.

[事实] He says some people from the first treatment-resistant depression trial remain well and back at work, while the majority have relapsed to his knowledge.

[事实] He describes a difficult situation where trial participants may benefit from psilocybin therapy but cannot legally access it afterward.

[126:05] Legal Status and Real-World Risk

[事实] Huberman distinguishes academic trials, underground therapists, black-market access, pharma activity, FDA oversight, and law enforcement.

[事实] He warns that street-bought MDMA and psychedelics may be laced with fentanyl and says possession or sale can carry serious legal consequences.

[事实] Carhart-Harris says Oakland’s decriminalization changes police prioritization but is not the same as licensed legal sales.

[131:32] Regulation, Phase Three Trials, and Access

[事实] Carhart-Harris says phase three trials are the key licensing stage and typically require at least two successful trials before regulators consider approval.

[事实] He says MAPS had completed two phase three MDMA therapy trials for PTSD, with published first-trial results showing about 67% remission.

[事实] He says psilocybin therapy for treatment-resistant depression was entering phase three through Compass, with one public estimate pointing to 2026.

[事实] He expects licensed providers would need training, certification, consultation procedures, and physician availability for emergencies.

[139:49] Momentum, Safeguards, and Paradigm Shift

[事实] Carhart-Harris says psychedelic research centers and trials have expanded rapidly, including work on anorexia, fibromyalgia, methamphetamine use disorder, Parkinson’s disease, chronic lower back pain, bipolar disorder, OCD, and addiction.

[事实] He says schizophrenia was not being studied with psychedelics to his knowledge.

[事实] He and Huberman discuss scandals, boundary violations, and the need for safeguards and standards so the field does not repeat past failures.

[事实] Carhart-Harris says current psychiatric treatments have not fundamentally progressed since the 1950s and argues that psychedelic therapy is different because it is not simply a daily drug model.

播客点评/总结

[推测] The episode’s strongest value is that it connects subjective experience, clinical protocol, and neuroscience without reducing psychedelic therapy to only “brain chemicals” or only “mystical insight.” It gives listeners a useful map of why set, setting, guides, music, dosage, and integration matter.

[事实] Carhart-Harris repeatedly marks limits in the evidence: microdosing data are thin, some anorexia and fibromyalgia findings are not yet published, anatomical brain-change findings come from one study, and mechanisms remain only partly understood.

[推测] The discussion is best suited for listeners who want a rigorous overview of psychedelic science, clinical trial design, and mental health applications, rather than practical instructions for personal use.

[推测] Its main limitation is breadth: because the conversation covers many compounds and conditions, some topics are introduced as promising or intriguing without enough detail to settle safety, efficacy, access, or long-term outcome questions.